Company
Cvrx
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
19
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
CVRX
Nasdaq · CVRx, Inc.
Public float
$112M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$56.7M
Fiscal year ending Dec 31, 2025
Net income
-$53.3M
Fiscal year ending Dec 31, 2025
R&D spending
$11.1M
Fiscal year ending Dec 31, 2025
Cash
$58.7M
As of Sep 30, 2026
Long-term debt
$58.7M
As of Sep 30, 2026
Shares outstanding
28.5M
As of Oct 29, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | $9.0M | – | – |
| 2024 | – | $32.5M | – | – |
| 2021 | – | $133M | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2020 | Equity | $50.0M | $50.0M | 21 | Rule 506(b) | Form D ↗Jul 8, 2020 |
| May 31, 2016 | Equity | $75.3M | $93.0M | 20 | Rule 506(b) | Form D/A ↗May 31, 20193 amendments |
| Jun 28, 2013 | Equity | $29.6M | $45.0M | 12 | Rule 506Agent: Piper Jaffray & Co.Commissions $50K | Form D ↗Jul 15, 2013 |
Company details
From the company's latest Form D.
- Legal name
- CVRx, Inc.
- Headquarters
- Minneapolis, Minnesota
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1235912 ↗
Executives, directors and promoters
As listed on the latest Form D.
11 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart FailurePivotal-lookingRecruiting
NCT07232030 · 2,500 participants (planned) · Start Apr 24, 2026 · Primary completion Jan 2033
Device: Barostim System · For: Heart Failure; Heart Failure NYHA Class II; Heart Failure NYHA Class III
Sites: Mobile, Alabama; Los Angeles, California; Clearwater, Florida · 26 sites in all
- BATwire Implant Kit StudyTerminated
NCT04600791 · 93 participants · Start Jan 29, 2021 · Primary completion Aug 28, 2024
Device: BATwire Implant Kit · For: Heart Failure
Sites: Mesa, Arizona; Scottsdale, Arizona; Orlando, Florida · 10 sites in all
- Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)Terminated
NCT04502316 · 435 participants · Start Jun 26, 2020 · Primary completion May 14, 2026
Device: Barostim™ System · For: Heart Failure
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 46 sites in all
16 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.